Jifeng Feng

机构：Guangxi Zhuang Autonomous Region Health and Family Planning, Guangxi Maternal and Child Health Hospital · ORCID：0000-0002-7979-2391

发表论文 496 篇 · 总被引 34613 次 · h-index 64

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 186)
• Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study (2024 · 癌症：英文版 · 被引 48)
• Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial (2024 · The Lancet Respiratory Medicine · 被引 42)
• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
• CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma (2024 · Blood Advances · 被引 17)
• A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study (2024 · Cancer · 被引 17)